Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure

AIMS: Impairment of vascular function contributes to the progression of chronic heart failure (HF) by increasing the afterload. Treatment with selective sodium‐glucose cotransporter 2 (SGLT2) inhibitors improves the prognosis of HF, but the precise mechanisms remain unclear. The aim of this study wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolwelter, Julie, Bosch, Agnes, Jung, Susanne, Stabel, Lena, Kannenkeril, Dennis, Ott, Christian, Bramlage, Peter, Schiffer, Mario, Achenbach, Stephan, Schmieder, Roland E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712907/
https://www.ncbi.nlm.nih.gov/pubmed/34544205
http://dx.doi.org/10.1002/ehf2.13622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712907/
https://www.ncbi.nlm.nih.gov/pubmed/34544205
http://dx.doi.org/10.1002/ehf2.13622

Ejemplares similares